Skip to main content
Syncona Limited logo

Syncona Limited — Investor Relations & Filings

Ticker · SYNC ISIN · GG00B8P59C08 LEI · 213800X8MBI5VQITLW60 IL Financial and insurance activities
Open in API
Filings indexed 1,030 across all filing types
Latest filing 2020-02-12 Regulatory Filings
Country GG Guernsey
Listing IL SYNC

About Syncona Limited

https://www.synconaltd.com/

Syncona Limited is a life science investment company focused on founding, building, and funding a portfolio of healthcare businesses. The company's strategy is to identify and advance exceptional science to create globally leading companies capable of delivering transformational treatments to patients, particularly in areas with high unmet medical needs. Its portfolio is concentrated in innovative therapeutic areas, including gene therapy, cell therapy, and biologics. Syncona actively manages its companies to reach key value inflection points, aiming to generate significant long-term capital appreciation for shareholders through strategic events such as mergers, acquisitions, and other liquidity events.

Recent filings

Filing Released Lang Actions
Freeline presents clinical data at WORLDSymposium
Regulatory Filings Classification · 99% confidence The document begins with 'RNS Number : 8008C' and concludes with information about RNS, stating, 'This information is provided by RNS, the news service of the London Stock Exchange.' This strongly indicates a regulatory announcement disseminated via the RNS system. The content itself is an announcement by Syncona Limited regarding clinical data presented by its portfolio company, Freeline, at a medical symposium (WORLDSymposiumTM). This is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). Since it is a specific corporate update disseminated through the official regulatory news service, and it doesn't fit perfectly into other specific categories like Director's Dealing (DIRS) or Dividend Notice (DIV), the most appropriate classification is the general regulatory announcement category, RNS, as it is the mechanism of dissemination and the nature of the filing.
2020-02-12 English
Freeline publishes further data for FLT180a
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated '07 February 2020'. It announces that a portfolio company (Freeline) is presenting further clinical trial data at a conference. The content is a press release detailing scientific updates, trial progress, and valuation context related to an investment held by Syncona Limited. The presence of the RNS Number and the nature of the announcement (a corporate update disseminated via a news service) strongly indicates this is a regulatory news service announcement. Since it is a general corporate update that doesn't fit perfectly into specific categories like ER, IR, or CAP, the most appropriate classification is the general regulatory filing/news category, RNS.
2020-02-07 English
Quarterly Update
Earnings Release Classification · 100% confidence The document is identified by the 'RNS Number' header and explicitly states it is a 'Quarterly Update' covering the period from 1 October to 31 December 2019. It provides detailed financial performance metrics (Net assets, NAV total return, portfolio valuation) and operational updates for the quarter. This structure aligns perfectly with a comprehensive financial report for a period shorter than a year, which corresponds to the Interim / Quarterly Report (IR) definition. Although it mentions a Capital Markets Day, the core content is the quarterly performance review, not just an announcement of a report (RPA) or a general regulatory filing (RNS). Q3 2019
2020-02-04 English
Autolus announces additional data in AUTO3 at EHA
Legal Proceedings Report Classification · 99% confidence The document begins with an 'RNS Number' and is dated January 30, 2020. It is an announcement by Syncona Limited regarding an update from its portfolio company, Autolus Therapeutics, concerning clinical trial data (AUTO3) to be presented at a medical meeting (EHA-EBMT). The text explicitly states, 'The announcement can be accessed on Autolus' investor website...' and concludes with the standard footer: 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure—a brief announcement referencing external detailed information and originating from the RNS system—strongly indicates a general regulatory announcement rather than a full report (like 10-K or IR) or a specific financial event release (like ER or DIV). Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIRS, MANG, or DIV), the appropriate fallback category is Regulatory Filings (RNS). The document length is moderate (11,349 chars), but the content is clearly framed as an announcement of news/data presentation, not the data itself.
2020-01-30 English
Autolus announces pricing of public offering
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated January 23, 2020. The content announces that a portfolio company, Autolus Therapeutics, has priced a public offering of American Depositary Shares (ADSs) in the United States, raising approximately $80.0 million. This is a notification about a significant financing/fundraising activity involving the issuance of new securities by an associated company. This clearly falls under the definition of 'Capital/Financing Update' (CAP). Although it is distributed via RNS, the core subject matter is financing, making CAP the most specific classification over the general RNS fallback.
2020-01-23 English
Freeline to present further FLT180a data at EAHAD
Environmental & Social Information Classification · 99% confidence The document begins with an 'RNS Number' and explicitly states that the information is provided by 'RNS, the news service of the London Stock Exchange.' The content is a brief announcement detailing that a portfolio company (Freeline) will present data at an upcoming congress (EAHAD) and that Syncona will provide details via an RNS announcement. Given the short length (3875 characters) and the nature of the announcement—informing the market about future data presentation and stating that details will follow via RNS—this fits the definition of a general regulatory announcement or a notice about an event, rather than a full report (like 10-K or IR). Since it is a direct regulatory news service release that doesn't fit a more specific category (like DIV, DIRS, or ER), the most appropriate classification is the general Regulatory Filings category (RNS).
2020-01-21 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.